X4 Pharmaceuticals, Inc. (XFOR) earnings
XFOR earnings moved a median of -3.32% by the close. Quarterly and annual XFOR reports and results, each read against the price at its own news timestamp. Back to the XFOR overview →
24 measured XFOR earnings events.
Where these XFOR earnings landedvs 24 measured XFOR earnings reactions
| Middle 50% of XFOR earnings reactions | -5.05% to +4.01% |
|---|---|
| Median reaction (to close) | -3.32% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 XFOR earnings events with a measured close landed between -5.05% and +4.01%; 38% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30 | SEC filing · Form 10-Q | +1.30% | +0.00% | |
| X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update | Press release | +1.30% | +0.00% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30 | SEC filing · Form 10-Q | +5.63% | +8.92% | |
| X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | +5.63% | +8.92% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Mar 31 | SEC filing · Form 10-Q | +0.24% | +4.04% | |
| X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | +0.24% | +4.04% | |
| Form 10-K X4 Pharmaceuticals, Inc For: Dec 31 | SEC filing · Form 10-K | -1.73% | +12.80% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30 | SEC filing · Form 10-Q | +1.34% | -4.57% | |
| X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | +1.34% | -4.57% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30 | SEC filing · Form 10-Q | -6.12% | -3.40% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Mar 31 | SEC filing · Form 10-Q | -6.31% | -8.98% | |
| X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates | Press release | -6.31% | -8.98% | |
| X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 | Press release | -1.39% | +4.00% | |
| Form 10-K X4 Pharmaceuticals, Inc For: Dec 31 | SEC filing · Form 10-K | -1.14% | +2.47% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Sep 30 | SEC filing · Form 10-Q | -5.31% | -46.41% | |
| X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -5.31% | -46.41% | |
| X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 | Press release | -0.20% | -3.29% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.54% | |
| X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates | Press release | -4.22% | -6.47% | |
| X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024 | Press release | -2.07% | -3.34% | |
| Form 10-Q X4 Pharmaceuticals, Inc For: Mar 31 | SEC filing · Form 10-Q | -1.85% | -3.70% | |
| X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates | Press release | +5.24% | +3.81% | |
| X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 | Press release | -0.83% | -6.67% | |
| Form 10-K X4 Pharmaceuticals, Inc For: Dec 31 | SEC filing · Form 10-K | +3.50% | +12.31% |
Keep exploring
More XFOR: analyst actions → · SEC filings → · XFOR overview →